Posted by Michael Wonder on 30 Mar 2020
FDA approves durvalumab for extensive-stage small cell lung cancer
30 March 2020 - On 27 March 2020, the FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer.
Efficacy of this combination in patients with previously untreated extensive-stage small cell lung cancer was investigated in CASPIAN, a randomized, multicenter, active-controlled, open-label, trial. The evaluation was based on the comparison of patients randomized to durvalumab plus chemotherapy vs. chemotherapy alone. The major efficacy outcome measure was overall survival. Additional efficacy outcome measures were investigator-assessed progression-free survival and objective response rate per RECIST v1.1.
